scholarly journals Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

2019 ◽  
Vol 10 ◽  
Author(s):  
Jiaxin Zhu ◽  
Tiantian Zhang ◽  
Jiahao Li ◽  
Junming Lin ◽  
Wenhua Liang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Tumor Mutation Burden ◽  
Mutation Burden

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system review

2020 ◽  
Author(s):  
kun zou(Former Corresponding Author) ◽  
Li Li ◽  
Shuailong Yang ◽  
Zhang Lei(New Corresponding Author)
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Mutation Burden ◽  
Mutation Burden

Abstract Background: We performed this meta-analysis to assess the prognostic value of tumor mutation burden (TMB) for patients with non-small cell lung cancer (NSCLC). Methods: Tow authors independently searched the studies in PubMed, web of science, Google Scholar, Cochrane library (from inception to November 2019), according to the key words “non-small cell lung cancer”, “tumor mutation burden”, “prognosis”. The studies were set up according to the inclusion/exclusion criteria. The estimate hazard ratio (HR), odds ratio (OR), risk ratio (RR) and their 95% confidence intervals (95% CIs) were set as effect measures. All analyses were performed by STATA 12.0. Results:28 studies were involved in this meta-analysis, high TMB was associated with good overall survival (OS) (HR=0.53; 95% CI: 0.42-0.67, p<0.001), progression-free survival (PFS) (HR = 0.53; 95% CI: 0.46-0.62, p<0.001), durable clinical benefits (RR = 2.27; 95% CI: 1.79-2.89, P<0.001), and object response rate (RR = 2.27; 95% CI: 1.80-2.85; p<0.001) in patients treated with immune checkpoint inhibits (ICIs). For treated with non-ICIs, poor PFS (HR = 1.62; 95% CI: 1.27-2.07, p<0.001) and OS (HR = 1.56; 95% CI: 1.30-1.87, p=0.001) was found in high TMB. Compared with chemotherapy, ICIs treatment alone had better OS (HR = 0.68; 95% CI: 0.56 to 0.82, p<0.001) and PFS (HR = 0.64; 95% CI: 0.55 to 0.76, p<0.001) for patients with high TMB, however, for low TMB patients, no benefit was found in ICIs treatment. TMB was correlated with EGFR status (OR = 0.28; 95% CI: 0.08- 0.95; p= 0.040), ECOG score (OR = 1.79; 95% CI: 1.09-2.92; p=0.021) and smoking history (OR = 6.01; 95% CI: 1.28 - 28.13; p=0.023). Conclusions: TMB was associated with better survival in cancer patients receiving immunotherapy, and worse survival in cancer patients receiving non-ICIs. Compared with chemotherapy, ICIs was more effective in high TMB patients, but not in low TMB patients.

scholarly journals The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Zhang Nan ◽  
Wang Guoqing ◽  
Yu Xiaoxu ◽  
Mi Yin ◽  
He Xin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Cell Lung Cancer ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Nonsmall Cell Lung Cancer ◽  
Tumor Mutation Burden ◽  
Mutation Burden ◽  
Nsclc Patients

Background. Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer, and the majority of NSCLC patients are diagnosed at the advanced stage. Chemotherapy is still the main treatment at present, and the overall prognosis is poor. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs) as the representative have been extensively applied for treating various types of cancers. Tumor mutation burden (TMB) as a potential biomarker is used to screen appropriate patients for treatment of ICIs. To verify the predictive efficacy of TMB, a systematic review and meta-analysis were conducted to explore the association between TMB and ICIs. Method. PubMed, EMBASE, Cochrane Library, and son on were systematically searched from inception to April 2020. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were estimated. Results. A total of 11 studies consisting of 1525 nonsmall cell lung cancer (NSCLC) patients were included. Comparison of high and low TMB: pooled HRs for OS, 0.57 (95% CI 0.32 to 0.99; P = 0.046 ); PFS, 0.48 (95% CI 0.33 to 0.69; P < 0.001 ); ORR, 3.15 (95% CI 2.29 to 4.33; P < 0.001 ). Subgroup analysis values: pooled HRs for OS, 0.75 (95% CI 0.29 to 1.92, P = 0.548 ) for blood TMB (bTMB), 0.44 (95% CI 0.26 to 0.75, P = 0.003 ) for tissue TMB (tTMB); for PFS, 0.54 (95% CI 0.29 to 0.98, P = 0.044 ) and 0.43 (95% CI 0.26 to 0.71, P = 0.001 ), respectively. Conclusions. These findings imply that NSCLC patients with high TMB possess significant clinical benefits from ICIs compared to those with low TMB. As opposed to bTMB, tTMB was thought more appropriate for stratifying NSCLC patients for ICI treatment.

scholarly journals Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients

Aging ◽  
2021 ◽  
Author(s):  
Linglong Peng ◽  
Yang Li ◽  
Haitao Gu ◽  
Ling Xiang ◽  
Yongfu Xiong ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Antitumor Immunity ◽  
Tumor Mutation Burden ◽  
Mutation Burden

scholarly journals Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis

2019 ◽  
Vol 30 ◽  
pp. v25 ◽  
Author(s):  
M.G. McNamara ◽  
T. Jacobs ◽  
M. Frizziero ◽  
R. Pihlak ◽  
A. Lamarca ◽  
...  
Keyword(s):  
Systematic Review ◽  
Solid Tumors ◽  
Meta Analysis ◽  
Tumor Mutation Burden ◽  
Mutation Burden
Sign in / Sign up

Export Citation Format

Share Document